References
- Young R C., Ozols R F., Myers C E. The anthracycline antineoplastic drugs. N Engl J Med 1982; 305: 138–53
- Christer P, Lbnnqvist B, Gahrton G, Lockner D, Peterson C. Reducing the cardiotoxicity of anthra-cyclines by complex-binding to DNA: Report of three cases. Cancer 1981; 48: 1531–4
- Sewa S L., Benjamin R S., Mackay B, Ewer M, Wallace S, Valdivieso M, Rasmussen S L., Blumenschein G R., Freireich E J. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med 1982; 96: 133–9
- Rahman A, More N, Schein P. Doxonibicin-induced chronic cardiotoxicity and its protection by liposomal administration. Cancer Res 1982; 42: 1817–25
- Lenzhofer R, Schneeweiss B, Rameis H. Phar-makokinetik und akute kardiale ToxizitStszeichen unter Doxorubicintherapie. Wien Klin Wochenschr 1983; 95: 52–5
- Lenaz L, Page J A. Cardiotoxicity of adriamycin and related anthracyclines. Cancer Treatment Rev 1976; 3: 111–20
- Von Hoff D D., Rozencweig M, Layard M. Daunomycin-induced cardiotoxicity in children and adults. A review of 110 cases. Am J Med 1977; 62: 200–8
- Wortman J E., Lucas V S., Schuster E. Sudden death during doxorubicin administration. Cancer 1979; 44: 1588–91